ReviewJournal of clinical medicine2026
Systemic Citrate Toxicity During Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regional citrate anticoagulation (RCA) is the preferred anticoagulation strategy for continuous kidney replacement therapy (CKRT) because it prolongs circuit lifespan while reducing bleeding complications compared with systemic heparin. Although generally safe, systemic citrate accumulation remains the principal metabolic complication of RCA and occurs when citrate delivery exceeds the combined metabolic and extracorporeal capacity for citrate elimination. This narrative review summarizes current evidence regarding citrate metabolism, the pathophysiological mechanisms of citrate accumulation, associated risk factors, biochemical diagnosis, monitoring strategies, and therapeutic management. Citrate metabolism depends predominantly on mitochondrial oxidative capacity rather than hepatic function alone, making circulatory shock and impaired tissue perfusion the principal determinants of citrate intolerance, whereas isolated liver dysfunction is often well tolerated. Systemic citrate accumulation is characterized by a distinctive biochemical profile including ionized hypocalcemia, an increased total-to-ionized calcium ratio, escalating calcium infusion requirements, high anion-gap metabolic acidosis, and frequently hyperlactatemia, while overt clinical manifestations usually occur late. Consequently, early recognition relies on structured biochemical monitoring and interpretation of serial trends rather than isolated measurements. Management should focus on restoring the balance between citrate delivery and citrate elimination by reducing citrate exposure when appropriate, optimizing extracorporeal citrate removal, correcting metabolic abnormalities, and improving tissue perfusion. Contemporary RCA practice should therefore emphasize individualized physiological assessment and integrated biochemical monitoring to facilitate early recognition, prevent progression to overt toxicity, and preserve the well-established safety and efficacy of RCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.